Hubbry Logo
search
search button
Sign in
Historyarrow-down
starMorearrow-down
Hubbry Logo
search
search button
Sign in
Insulin glulisine
Community hub for the Wikipedia article
logoWikipedian hub
Welcome to the community hub built on top of the Insulin glulisine Wikipedia article. Here, you can discuss, collect, and organize anything related to Insulin glulisine. The purpose of the hub is to connect people, foster deeper knowledge, and help improve the root Wikipedia article.
Add your contribution
Inside this hub
Insulin glulisine

Insulin glulisine
PDB: 6gv0
Clinical data
Trade namesApidra, Apidra Solostar
AHFS/Drugs.comMonograph
MedlinePlusa607033
License data
Pregnancy
category
Routes of
administration
Subcutaneous, intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
PDB ligand
Chemical and physical data
FormulaC258H384N64O78S6
Molar mass5822.64 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Insulin glulisine, sold under the brand name Apidra among others, is a rapid-acting modified form of medical insulin used for the treatment of diabetes. It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[2] When injected subcutaneously, it appears in the blood earlier than regular human insulin (RHI).[4] Intravenous injections may be used for extreme hyperglycemia.[2] It was developed by Sanofi-Aventis.

The most common side effects include hypoglycaemia (low blood glucose levels).[3]

Insulin glulisine was approved for medical use in the United States[2][5] and in the European Union[3] in 2004.

Medical uses

[edit]

Insulin glulisine is indicated for the treatment of diabetes.[2][3]

Mechanism behind the rapid bioavailability

[edit]

The monomer-monomer interactions are weaker in insulin glulisin compared to unmodified human insulin, and therefore, it does not as readily form dimers and hexamers, which are dominant in unmodified insulin.[medical citation needed] Due to their large size, insulin hexamers need to break up into dimers or monomers before they are able to enter the blood and become biologically active.[medical citation needed] Specifically, the B3 mutation causes electrostatic repulsion in the hexamer to arginine-22 in the B chain of other insulin molecules in the same hexamer, while the B29 mutation causes fewer hydrogen bonds to stabilize the dimer.[medical citation needed] Furthermore, the isoelectric point of insulin glulisine insulin, which is shifted from 5.5 (of unmodified human insulin) to 5.1, increases the solubility at physiological pH levels.[6]

References

[edit]
Add your contribution
Related Hubs